SCHEMBL4477563

SCHEMBL4477563

CN1CCN(c2ccc(F)cc2CC2CCCNC2=O)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALK Q9UM73 2/20 0.41
DPP4 P27487 3/20 0.38
DPP8 Q6V1X1 1/20 0.38
MAPK7 Q13164 2/20 0.36
LRRK2 Q5S007 1/20 0.36
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
GRIA4 P48058 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
CRBN Q96SW2 1/20 0.35
PARP1 P09874 3/20 0.35
PSEN1 P49768 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1739004 0.93 ALK (0.47) ALDH1A1L3MBTL1ALKDPP4DPP8
SCHEMBL4477924 0.85 NCF1 (0.47)
SCHEMBL4479143 0.81 MAPT (0.39) ALDH1A1L3MBTL1ALKMAPK7LRRK2
SCHEMBL1738754 0.79 CCR4 (0.39) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL1737562 0.77 NCF1 (0.46) ALK
SCHEMBL4732267 0.77 NCF1 (0.46) ALK
SCHEMBL5611262 0.77 NCF1 (0.46) ALK
SCHEMBL27667594 0.76 ALDH1A1 (0.41) ALDH1A1L3MBTL1ALKMAPK7LRRK2
SCHEMBL4480301 0.76 NCF1 (0.54) ALDH1A1
SCHEMBL5813092 0.75 CXCR4 (0.37) CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7479559-B2 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation PFIZER INC. (US) 2009-01-20 US disclosed
US-20050245521-A1 Novel benayl(idene)-lactam derivatives PFIZER INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245521-A1 Novel benayl(idene)-lactam derivatives HTR1E, HTR1D, HTR1A ALDH1A1 411/4885L3MBTL1 1098/4885ALK 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.